Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
natalizumab treatment · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Plasma exchange | PROCEDURE | - |
| natalizumab treatment | DRUG | - |
Inclusion Criteria: * considered by the Investigator to be free of signs and symptoms suggestive of any serious opportunistic infection * willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including interferon beta and glatiramer acetate) for th...
Natalizumab is being studied for multiple sclerosis, including relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis, as well as graft versus host disease. It is also being investigated in clinical trials for acute ischemic stroke and focal epilepsy. Natalizumab is an investigational therapy and is not approved for these uses.
Natalizumab is a small molecule that targets alpha-4 integrin, a protein involved in immune cell migration. By binding to this target, it is thought to reduce the movement of immune cells into the central nervous system, which is relevant to its study in multiple sclerosis and other neurological conditions.
Natalizumab is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol BIIB. Biogen is conducting clinical research on natalizumab across multiple indications, including multiple sclerosis and other neurological disorders.
Natalizumab is in Phase 2 clinical development. It has completed five clinical trials, including Phase 2 studies in acute ischemic stroke and focal epilepsy. Natalizumab is an investigational drug and has not been approved by regulatory authorities for the indications being studied.
Natalizumab has completed several clinical trials, including NCT01955707 and NCT02730455 for acute ischemic stroke, NCT03283371 for focal epilepsy, and NCT00424788 for relapsing forms of multiple sclerosis. These trials were randomized, double-blind, and placebo-controlled, with a total enrollment of 2795 participants.
Natalizumab is the same as Tysabri, a brand name for the drug. Tysabri is an established treatment for relapsing forms of multiple sclerosis. In ongoing research, natalizumab is being evaluated for additional conditions such as primary progressive multiple sclerosis and graft versus host disease.